1 / 31

Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008

Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman. Forward Looking Statements.

manju
Download Presentation

Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Merrill LynchGlobal Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman

  2. Forward Looking Statements Certain statements contained herein including, without limitation, statements containing the words “believes,” “anticipates,” “intends,” “expects” and words of similar import, constitute forward-looking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  3. The Journey So Far 1990 • Revenues $0.5 million • Staff 5 2006 • Revenues $456 million • EPS $1.33 • Staff 4,300 2007 Guidance • Revenues $615 - $625m • EPS $1. 82 - $1.85 • Staff 5,500 2008 Guidance • Revenues $750 - $770m • EPS $2.27 - $2.36 • Staff 6,250

  4. Global Full Service Clinical Development EU 41% Revenue by Region ROW 6% US 53%

  5. Global sites Conducting Clinical Trials in over 100 countries from 67 Locations in 37 countries 5600 Employees67 Locations37 Countries

  6. Market Environment

  7. Strong Market Environment with... • Fundamental R&D Spending Growth Trend 6%- 8% p.a. • Phase II / III pipelines strengthening • Increased Outsourcing • Being accelerated by activity & funding in Biotech / Speciality • Globalisation of clinical research • Cost containment pressures • Evidence that projects, where CROs are engaged, complete faster than “internal only” studies* • Growth c.15% p.a. since 2001* • Increasing Regulation • More patients/ more studies • Post marketing surveillance *Source: Tufts Centre for Study of Drug Development

  8. …US Biotech Funding Environment continuing to grow Biotech fund raising ($billions) $Billion Source: Burrill and Company

  9. …significant growth in the number of companies with active clinical projects,…. Number of companies running clinical projects Source: Informa Health

  10. …which is enriching pipelines. 2002 – 2006 46% Growth Phase I – II Source: IMS R&D Focus, Dec 2006 and previous year SMRs

  11. … and significant growth in the number of active INDs,… 49% Increase since 2000 Number of Active INDs Source: FDA

  12. ICON in this Market Environment

  13. Strong Gross Business wins has led to… ICON Gross Business Wins - Last 9 Quarters ($ millions)

  14. .. excellent Net New Business wins and very strong book to bill ratios… Net Business Wins Book to Bill Ratio

  15. …leading to record Total Backlog levels. ($ millions)

  16. From this backlog, coverage of next 4 quarters revenues is robust…….. % coverage of next 4 quarters forecast revenues Value of backlog forecast to be earned in next 4 quarters

  17. …..and the customer base continues to diversify. Client Concentration 2005, 2006, YTD 2007

  18. YTD ‘07 Revenue Breakdown Estimate 2007 Revenue $620m* Revenue by Customer Segment Revenue by Therapeutic Area *Mid Point of Calendar year Guidance issued October 2007

  19. Revenue Growth v Peers: Net Revenue CAGR between 2000 and 2006 *Source SEC Filings

  20. Strategy

  21. Core Strategy is Organic Growth, with acquisitions adding new services or scale. • Capitalise on market fundamentals to drive organic growth in all business units. • Expand geographic footprint to exploit globalisation. • Pursue acquisitions to enhance depth and scale of current operations and to add additional complementary services e.g. • Phase I • Bioanalytical / Biomarkers • Therapeutic specialists • Safety / Phase IV • Patient Recruitment • Staffing • Cross-sell services to grow sales and margin

  22. Financial Performance

  23. Recent Financial Performance ($ millions, except EPS; includes stock option expense)

  24. Recent Financial Performance ($ millions)

  25. Net Revenue CAGR in excess of 30% over 6 Years $760(E)** CAGR 31.6% FY2008(E) (E) *Mid Point of Calendar year Guidance issued October 2007 **Mid Point of Calendar year Guidance issued December, 2007

  26. Earnings Per Share Growth $2.32(E)** CAGR 25.9% (E) FY2008(E) *Mid Point of Guidance issued October 2007 **Mid Point of Guidance issued December 2007

  27. Summary Balance Sheet and Cash Flow ($ millions)

  28. Improving Margins

  29. Quarterly Operating margins have beenimproving and …. Turnaround in Lab * Includes an estimated SFAS 123 non cash stock compensation charge for the 2005 figures

  30. ….further margin improvement should arisethrough 2008 • Further volume growth in Lab • Significantly improved performance from Phase I and Consultancy businesses • Bringing Japan from investment phase to profitability • Expanding margins in Phase II – IV through leverage

  31. Investment Case Summary • Top Global Clinical CRO - #4 • Outstanding record of growth • Strong market fundamentals • Excellent strategic position • Strong balance sheet • Margin expansion opportunity

More Related